Hengrui Medicine’s latest semi‑annual report shows the company’s fundamentals staying solid while its innovative drug portfolio gains momentum. By the end of June, Hengrui had nine new marketing applications approved by China’s regulator, with 17 trials moving into Phase III, 22 into Phase II and ten entering Phase I for the first time. The firm earned 67 clinical trial approvals, six breakthrough‑therapy designations and three priority‑review slots, highlighting the promise of its pipeline. Patents are also piling up – 157 new filings in Greater China and 332 abroad, bringing the total to over 2,200 granted patents worldwide. Clinically, the company celebrated major milestones: its HER3‑targeted antibody‑drug conjugate Rukanzoluzumab met its primary endpoint in a Phase III lung‑cancer study and is awaiting approval, while a bladder‑cancer ADC combo showed encouraging Phase II results and is set to start Phase III enrollment. In the metabolic arena, Hengrui’s GLP‑1/GIP combo pills delivered an average 12 % weight loss in Phase II, and its oral GLP‑1 candidate HRS‑7535 achieved similar results, prompting multiple Phase III launches. Sales of non‑oncology innovative drugs jumped nearly 74 % year‑on‑year to ¥2.55 billion, now accounting for almost 29 % of the company’s innovative‑drug revenue. With new indications rolling out for several existing products and a robust pipeline of 26 Class 1 and six Class 2 new drugs, Hengrui is poised for continued high‑speed growth.
Read more